ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.73221
0.17%
Brent Oil
84.34
-0.30%
Bitcoin
64,584.86
6.26%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acceleron Pharma Inc (XLRN)

  7. Acceleron Pharma Inc (XLRN) Noticias

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
30/04/201806:00Business WireAcceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018NASDAQ:XLRNAcceleron Pharma Inc
26/04/201807:00Business WireAcceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual MeetingNASDAQ:XLRNAcceleron Pharma Inc
26/04/201806:00Business WireAcceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology An...NASDAQ:XLRNAcceleron Pharma Inc
16/04/201815:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
13/04/201815:21Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
13/04/201815:19Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
04/04/201815:42Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
12/03/201806:00Business WireAcceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH)...NASDAQ:XLRNAcceleron Pharma Inc
28/02/201806:04Business WireAcceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & NerveNASDAQ:XLRNAcceleron Pharma Inc
27/02/201816:49Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XLRNAcceleron Pharma Inc
27/02/201815:27Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
27/02/201815:05Business WireAcceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
20/02/201806:00Business WireAcceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018NASDAQ:XLRNAcceleron Pharma Inc
14/02/201813:19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
13/02/201816:49Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
08/02/201815:01Business WireAcceleron Announces Appointment of Chief Commercial OfficerNASDAQ:XLRNAcceleron Pharma Inc
08/02/201809:47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XLRNAcceleron Pharma Inc
31/01/201806:00Business WireAcceleron to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
08/01/201810:05Business WireAcceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral DystrophyNASDAQ:XLRNAcceleron Pharma Inc
03/01/201806:00Business WireAcceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. ShermanNASDAQ:XLRNAcceleron Pharma Inc
02/01/201806:00Business WireAcceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
10/12/201708:00Business WireAcceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annu...NASDAQ:XLRNAcceleron Pharma Inc
05/12/201706:00Business WireAcceleron to Host Conference Call & Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meetin...NASDAQ:XLRNAcceleron Pharma Inc
28/11/201712:15Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
15/11/201715:01Business WireAcceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuireNASDAQ:XLRNAcceleron Pharma Inc
14/11/201715:01Business WireAcceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific ...NASDAQ:XLRNAcceleron Pharma Inc
07/11/201706:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
07/11/201706:00Business WireAcceleron Pharma Reports Third Quarter 2017 Operational and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
01/11/201708:19Business WireAcceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and ExpositionNASDAQ:XLRNAcceleron Pharma Inc
26/10/201706:00Business WireAcceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017NASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

NYSE
MRK
Merck
USI
USTECH100
US Tech 100
FX
EURMXN
Euro vs MXN
USOTC
BASFY
BASF (QX)
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
NYSE
MCD
McDonalds
AMEX
XLV
Health Care Select Sector
NYSE
VZ
Verizon Communications
NYSE
NKE
Nike
FX
EURUSD
Euro vs US Dollar
NASDAQ
AMZN
Amazon.com
AMEX
XLF
Financial Select Sector
NYSE
AXP
American Express
USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados